Lupin gets USFDA approval for Paraxetin tablets
Shital Jibhe / 23 Jan 2017
Lupin Limited has informed The Bombay Stock Exchange Ltd and National Stock Exchange Ltd. on January 23, 2017, that it has received final approval from the US Food and Drug Administration.
Lupin Limited has informed The Bombay Stock Exchange Ltd and National Stock Exchange Ltd. on January 23, 2017, that it has received final approval from the US Food and Drug Administration.
The company has received USFDA approval for Paraxetin Extended Release Tablets USP, 12.5 mg, 25 mg, which is a generic version of Apotex Technologies, Inc’s Paxil CR® tablets, 12.5 mg, 25 mg and 37.5 mg.
Lupin Ltd is a pharmaceuticals major based in Mumbai, having current market capitalisation of Rs 66,149.44 crore. The stock has is up today and has made intra-day high at Rs 1490, up by more than 1.50 per cent on Monday morning.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.